Organization
Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
3 abstracts
Abstract
Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: A single-center, single-arm, phase II trial.Org: Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Long-term liver and renal dysfunction in patients with metastatic renal cell carcinoma treated with TKI monotherapy: COMPARZ study post-hoc analysis.Org: Fudan University Zhongshan Hospital, Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Novartis Oncology, Novartis China,
Abstract
A novel prognostic model for oligometastatic renal cell carcinoma: COMPARZ study post-hoc analysis.Org: Fudan University Zhongshan Hospital, Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Novartis Oncology, Novartis China,